Qiagen N.v. · NYSE:QGEN
Qiagen — Investor Day (June 2024)
74 slides from Qiagen's investor day presentation, Jun 17, 2024
Slide 1: Committed to Solid Profitable Growth
COMMITTED TO SOLID PROFITABLE GROWTH Capital Markets Day June 17, 2024
Slide 2: Capital Markets Day Microsite
Photos and video recordings of participants will be taken during this event. These may be used CAPITAL MARKETS DAY MICROSITE for future publications and marketing by QIAGEN, including their website and social media channels. Webcast, presentation, infographic and additional information to be found h
Slide 3: 2024 QIAGEN Capital Markets Day Agenda
2024 QIAGEN CAPITAL MARKETS DAY AGENDA John Gilardi 12:00 – 12:10 Introduction 10 Vice President, Corporate Communications and Investor Relations Thierry Bernard 12:10 – 12:40 2028 strategy 30 Chief Executive Officer Sample technologies and Nitin Sood 12:40 – 13:00 20 QIAcuity dPCR Senior Vice Presi
Slide 4: Today's Presenters
TODAY'S PRESENTERS Thierry Bernard Roland Sackers Chief Executive Officer Chief Financial Officer Thierry Bernard joined QIAGEN in 2015 to lead our growing presence in molecular Roland Sackers has been Chief Financial Officer at QIAGEN since 2004 and a member diagnostics. He was named Chief Executiv
Slide 5: Today's Presenters
TODAY'S PRESENTERS Nitin Sood Fernando Beils Jonathan Sheldon Senior Vice President, Senior Vice President, Senior Vice President, Life Sciences Molecular Diagnostics QIAGEN Digital Insights Nitin Sood joined QIAGEN in 2023 as Senior Vice Fernando Beils joined QIAGEN in 2023 as Senior Vice Dr. Jonat
Slide 6: Forward looking and intended use statements
Forward looking and intended use statements Safe Harbor Statement: Certain statements contained in this presentation may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1
Slide 7: 2028 Strategy: Committed to Solid Profitable Growth
2028 STRATEGY Thierry Bernard Chief Executive Officer COMMITTED TO SOLID PROFITABLE GROWTH June 17, 2024 Capital Markets Day 2024 7
Slide 8: The Value of Biology Has Never Been Stronger
THE VALUE OF BIOLOGY HAS NEVER BEEN STRONGER Crucial to Improving Direct impact advancing healthcare on your science for all lives June 17, 2024 Capital Markets Day 2024 8
Slide 9: QIAGEN More Focused and Stronger Than Ever
QIAGEN MORE FOCUSED AND STRONGER THAN EVER QIAGEN LIFE MOLECULAR customers SCIENCES DIAGNOSTICS ~$13-14 bn QIAGEN addressable product Sample technologies market groups ~4-6% (2028) ENHANCING PCR CAGR GROWTH Genomics / NGS ~$11 bn AND VALUE addressable Diagnostic solutions market (2024) +7% >85% >60,
Slide 10: Well-Balanced Across Key Market Dimensions
WELL-BALANCED ACROSS KEY MARKET DIMENSIONS 2023 net sales: ~$2 bn Balanced portfolio Diversified product base Strong recurring revenues Global presence 12% 16% 34% 32% 36% 47% Product Product Customers 53% Regions groups types 3% 15% 88% 52% 12% Molecular Diagnostics Sample technologies Consumables
Slide 11: Leveraging a Trusted Brand Known for Quality
LEVERAGING A TRUSTED BRAND KNOWN FOR QUALITY Pharma / CROs Academia / hospitals Serving >500,000 customers from basic research to Clinical labs / test facilities Public agencies clinical testing CRO – Contract Research Organization June 17, 2024 Capital Markets Day 2024 11
Slide 12: From Academia to Clinical Labs, a Continuum of Differentiated Solutions
FROM ACADEMIA TO CLINICAL LABS, A CONTINUUM OF DIFFERENTIATED SOLUTIONS Samples Sample preparation Detection Insights PCR Any Sample Genomics / NGS biological technologies sample Diagnostic solutions LIFE SCIENCES CUSTOMERS MOLECULAR DIAGNOSTICS CUSTOMERS Academic labs Hospitals / Decentralized heal
Slide 13: Strategy: Committed to Solid Profitable Growth
STRATEGY: COMMITTED TO SOLID PROFITABLE GROWTH OUR 2028 TARGETS Sharpen focus on growth pillars to At least $2 bn sustain profitable growth net sales CER from pillars in 2028 ~7% At least 250 bps Net sales CER CAGR Drive efficiency and digitization to fuel (2024-28) growth investments and profitabil
Slide 14: Sharpening Focus on Pillars for Profitable Growth
// SHARPEN FOCUS ON GROWTH PILLARS SHARPENING FOCUS ON PILLARS FOR PROFITABLE GROWTH NeuMoDx: Our growth drivers: Disciplined portfolio management Sharpened focus on profitable growth # Current position QIAcuity dPCR PCR #2 Reduce commercial support in stages through 2025 Accelerate Responsibly tran
Slide 15: Growth Pillars to Contribute ≥$2 bn Sales CER in 2028
// SHARPEN FOCUS ON GROWTH PILLARS GROWTH PILLARS TO CONTRIBUTE ≥$2 BN SALES CER IN 2028 Accelerate investments for growth Build on proven leadership QIAcuity QIAGEN Digital Sample QIAstat-Dx QuantiFERON QuantiFERON dPCR Insights (QDI) technologies Growth pillar Digital PCR for Syndromic testing for
Slide 16: ≥31% Adjusted Operating Income Margin in 2028
// DRIVE EFFICIENCY AND DIGITIZATION INITIATIVES TO FUEL GROWTH INVESTMENTS AND ACHIEVE ≥31% ADJUSTED OPERATING INCOME MARGIN IN 2028 Operational excellence Digitization Positioning QIAGEN for stronger profitable growth Accelerating growth and efficiency across QIAGEN Organizational design Portfolio
Slide 17: Focusing on Targeted Capital Deployment
// ENSURE DISCIPLINED CAPITAL ALLOCATION FOCUSING ON TARGETED CAPITAL DEPLOYMENT Organic Profitable targeted investments investments Strong cash flow and Focused healthy M&A Value-creating transactions balance sheet Shareholder Committed to a higher level of returns to shareholders returns June 17,
Slide 18: Embracing ESG for All Stakeholders
// DELIVER THROUGH ACCOUNTABLE, EMPOWERED AND REINVIGORATED LEADERSHIP EMBRACING ESG FOR ALL STAKEHOLDERS Top ESG ratings Environmental responsibility Net zero carbon emission target (2050) Investing in people 36% female leadership (2023) ≥40% target (2027) Serving society >50 public health partners
Slide 19: Executing Our Strategy with Empowered QIAGENers
// DELIVER THROUGH ACCOUNTABLE, EMPOWERED AND REINVIGORATED LEADERSHIP EXECUTING OUR STRATEGY WITH EMPOWERED QIAGENERS Great Great Great Great Great Great Place Place Place Place Place Place ~6,000 To Work Certified ® NOV 2023–NOV 2024 USA To Work ® Certificada DEC 2022–DEC 2023 MEXICO To Work Certi
Slide 20: Reinvigorated Leadership Team Dedicated to Deliver
// DELIVER THROUGH ACCOUNTABLE, EMPOWERED AND REINVIGORATED LEADERSHIP REINVIGORATED LEADERSHIP TEAM DEDICATED TO DELIVER Supervisory Board Executive Committee Presenting today Lawrence A. Rosen Metin Colpan Chair Co-founder of QIAGEN Thierry Bernard Roland Sackers Joined in 2013 Chief Executive Off
Slide 21: Our 2028 Targets
STRATEGY: COMMITTED TO SOLID PROFITABLE GROWTH OUR 2028 TARGETS Sharpen focus on growth pillars to At least $2 bn sustain profitable growth net sales CER from pillars in 2028 ~7% At least 250 bps Net sales CER CAGR Drive efficiency and digitization to fuel (2024-28) growth investments and profitabil
Slide 22: Endless Possibilities with DNA and RNA
ENDLESS POSSIBILITIES WITH Nitin Sood DNA AND RNA Senior Vice President Life Sciences Business Area LIFE SCIENCES BY QIAGEN June 17, 2024 Capital Markets Day 2024 22
Slide 23: Leading from the First Step in Lab Workflows
LEADING FROM THE FIRST STEP IN LAB WORKFLOWS Samples Sample preparation Detection Insights PCR QIAcuity dPCR Any Genomics / NGS Sample biological technologies QIAGEN Digital Insights sample Diagnostic solutions LIFE SCIENCES CUSTOMERS MOLECULAR DIAGNOSTICS CUSTOMERS Academic labs Hospitals / Decentr
Slide 24: Strong Portfolio Building on Sample Prep Leadership
STRONG PORTFOLIO BUILDING ON SAMPLE PREP LEADERSHIP Sample PCR / Genomics / technologies Nucleic acid amplification NGS QIAGEN Sample PCR Digital PCR NGS Bioinformatics portfolio technologies Customers Academia / Research Pharma / Translational Applied testing Microbiome and Cancer research Biopharm
Slide 25: Endless Possibilities with DNA and RNA
Opportunity Strong demand for advanced, reliable solutions to support Life Sciences research, pharma and applied testing markets Why we win ENDLESS One of the most recognized brands in labs, known for quality and expertise from the first step of molecular workflows POSSIBILITIES WITH DNA AND RNA Str
Slide 26: Sample Technologies
// SAMPLE TECHNOLOGIES Sample technologies Laboratory workflow Differentiated solutions for PCR Valuable Biological Sample modular, integrated workflows molecular sample technologies insights Fast time to result, scalability Critical step in and ease of use dPCR HIGH-QUALITY molecular SAMPLE PREP wo
Slide 27: Leader in the First Step of Lab Workflows
// SAMPLE TECHNOLOGIES LEADER IN THE FIRST STEP OF LAB WORKFLOWS Key achievements Comprehensive ANY >350 DNA / RNA consumables portfolio biological sample different sample kits target analytes >120 mn QIAGEN preparations e.g., tissue, cells, blood, for manual and sold per year including variations s
Slide 28: Extending Comprehensive Automation Offering
// SAMPLE TECHNOLOGIES EXTENDING COMPREHENSIVE AUTOMATION OFFERING >14,400 placements(1) Benchtop system Launch 2026 NEW Research / applied QIAcube Validated and customized protocols QIAsprint testing Connect Connect Up to 12 samples per run Up to 192 samples per run Large menu supporting applicatio
Slide 29: Focused Strategy to Drive Mid-Term Growth
// SAMPLE TECHNOLOGIES FOCUSED STRATEGY TO DRIVE MID-TERM GROWTH ≥$750 mn Sample technologies Liquid Pathogen net sales CER target Expand in state-of-the-art Microbiome biopsy detection (2028) applications with new consumables Extend #1 position with improved handling through new consumables kits En
Slide 30: QIAcuity dPCR
// QIAcuity dPCR QIAcuity dPCR Quantitative PCR QIAcuity dPCR Next-generation (qPCR) Enabling novel applications sequencing (NGS) e.g., Cell and Gene Therapy e.g., liquid biopsy In-depth insights dPCR – Lower sensitivity and precision High sensitivity and precision and high precision More accurate t
Slide 31: Targeting Research to Clinical Healthcare
// QIAcuity dPCR TARGETING RESEARCH TO CLINICAL HEALTHCARE Key achievements Scalable systems Low- to high- throughput capabilities QIAcuity One QIAcuity Four QIAcuity Eight >2,000 cumulative placements since launch Academia Overcoming entry barrier vs. qPCR Translational and Ease of use Fully integr
Slide 32: Significant Investments into QIAcuity dPCR
// QIAcuity dPCR SIGNIFICANT INVESTMENTS INTO QIACUITY DPCR ≥$250 mn QIAcuity net sales CER target (2028) Target Extend Accelerate commercialization new applications into clinical use >3x increase NEW Add >100 assays NEW QIAcuity-Dx NEW of sales specialists for market menu expansion for CGT, version
Slide 33: Case Study: Enabling Accurate Therapy
// QIAcuity dPCR CASE STUDY ENABLING ACCURATE THERAPY CAR-T therapy U.S. children's hospital Revolutionary targeted cancer treatment QIAcuity-enabled vector release assay included in FDA submission One-stop shop ensuring high quality and support Patient's T-cells are collected and modified to recogn
Slide 34: Net Sales 2028 Life Sciences Targets
NET SALES 2028 LIFE SCIENCES TARGETS(1) ENDLESS POSSIBILITIES WITH DNA AND RNA Sample technologies Sample technologies ≥$750 mn Leverage #1 position through new automation solutions and cutting-edge applications vs. >$650 mn (2024) QIAcuity dPCR QIAcuity dPCR ≥$250 mn Seize dynamic market opportunit
Slide 35: Decisive When It Matters
Fernando Beils DECISIVE WHEN IT MATTERS Senior Vice President Molecular Diagnostics Business Area MOLECULAR DIAGNOSTICS BY QIAGEN June 17, 2024 Capital Markets Day 2024 35
Slide 36: Enabling Labs Through Molecular Testing
ENABLING LABS THROUGH MOLECULAR TESTING Samples Sample preparation Detection Insights PCR QIAcuity dPCR Any Genomics / NGS Sample biological technologies QIAGEN Digital Insights sample Diagnostic solutions QuantiFERON | QIAstat-Dx LIFE SCIENCES CUSTOMERS MOLECULAR DIAGNOSTICS CUSTOMERS Academic labs
Slide 37: Focusing on Unmet Medical Needs
FOCUSING ON UNMET MEDICAL NEEDS Sample Diagnostic PCR / Nucleic acid Genomics / technologies solutions amplification NGS QIAGEN Sample Blood-based Multiplex Digital PCR Bioinformatics portfolio technologies disease detection syndromic testing Reference / Physicians / Public health Customers Hospital
Slide 38: Decisive When It Matters
Opportunity Targeting fast-growing markets with demand for novel diagnostics Why we win Top leadership positions through a differentiated portfolio in areas with DECISIVE unmet medical needs WHEN IT MATTERS Strategic priorities QuantiFERON Expand #1 latent Tuberculosis (TB) position through skin tes
Slide 39: QuantiFERON: A Highly Contagious and Lethal Bacterial Infection
// QuantiFERON QuantiFERON TUBERCULOSIS: A HIGHLY CONTAGIOUS AND LETHAL BACTERIAL INFECTION 1 in 4 Broad health risk Global relevance people have a latent TB bacterial infection 1 in 10 EMEA of these people will develop an Immunocompromised ~10 mn active TB bacterial infection patients North America
Slide 40: Best-Positioned Latent Tuberculosis Test
// QuantiFERON BEST-POSITIONED LATENT TUBERCULOSIS TEST QuantiFERON Tuberculin Key achievements Advantages to Specification blood test skin test skin test Customizable automated workflow High accuracy and specificity $408 mn 2023 net sales (+70% vs. 2019) Only one patient visit Electronic results Qu
Slide 41: Driving Skin Test Conversion with Unrivaled Automation
// QuantiFERON DRIVING SKIN TEST CONVERSION WITH UNRIVALED AUTOMATION ≥$600 mn QuantiFERON Leading automation advantage net sales CER target (2028) Automated Automated Increase liquid handling assay and result customer base Partnership with Diasorin to expand into Lyme disease Large potential in ski
Slide 42: QIAstat-Dx
// QIAstat-Dx QIAstat-Dx Use case: 3-year-old with severe but unspecific GI symptoms Traditional testing Syndromic testing Slow diagnosis and treatment Fast diagnosis enabling better decisions can lead to complexities treatment decisions IDENTIFYING UNKNOWN DISEASES AT Day 1 Day 1 One test within SP
Slide 43: QIAstat-Dx Offers Differentiated Features
// QIAstat-Dx QIASTAT-DX OFFERS DIFFERENTIATED FEATURES Key achievements Strong product capabilities Key differentiators Specification QIAstat-Dx Competition Workflow Additional >4,000 cumulative placements efficiency pathogens since launch Hands-on time ~1 min >5 min and safety on panels for for br
Slide 44: Expanding Global Presence and Differentiated Menu
// QIAstat-Dx EXPANDING GLOBAL PRESENCE AND DIFFERENTIATED MENU ≥$200 mn QIAstat-Dx net sales CER target (2028) Grow installed Small hospitals Medium hospitals Large hospital networks customer Public health labs Regional reference labs National reference labs base FDA submission 2024 Low-throughput
Slide 45: Offering New Solutions for Pharma Projects
// QIAstat-Dx AND QIAcuity-Dx OFFERING NEW SOLUTIONS FOR PHARMA PROJECTS QIAstat-Dx for NEW QIAcuity-Dx dPCR NEW #1 trusted genetic and other diseases for Precision Medicine Pharma partner 2 3 >30 14 master collaboration FDA Pharma partnerships Pharma partnerships agreements approvals New Precision
Slide 46: Net Sales 2028 Molecular Diagnostics Targets
NET SALES 2028 MOLECULAR DIAGNOSTICS TARGETS(1) DECISIVE WHEN IT MATTERS QuantiFERON QuantiFERON ≥$600 mn Expand #1 latent TB position through skin test conversion and complete automation advantages vs. >$450 mn (2024) QIAstat-Dx QIAstat-Dx ≥$200 mn Achieve #2 position with broader global presence a
Slide 47: Break
COMMITTED TO SOLID BREAK PROFITABLE GROWTH Capital Markets Day June 17, 2024 June 17, 2024 Capital Markets Day 2024 47
Slide 48: Powerful Analytics to Understand Genomics
POWERFUL ANALYTICS Jonathan Sheldon TO UNDERSTAND GENOMICS Senior Vice President QIAGEN Digital Insights Business Area BIOINFORMATICS BY QIAGEN June 17, 2024 Capital Markets Day 2024 48
Slide 49: Anchoring Genomics Offering with Leading Software
ANCHORING GENOMICS OFFERING WITH LEADING SOFTWARE Samples Sample preparation Detection Insights PCR Any Genomics / NGS Sample biological technologies QIAGEN Digital Insights sample Diagnostic solutions LIFE SCIENCES CUSTOMERS MOLECULAR DIAGNOSTICS CUSTOMERS Academic labs Hospitals / Decentralized he
Slide 50: QIAGEN Unlocking the Power of Genomics
QIAGEN UNLOCKING THE POWER OF GENOMICS Development Genomic data In 2003, the first human Today, any human genome genome took can be read in 13 years 5 hours Sequencing costs >$1 bn / genome $100 / sequencing run 2000 2010 2020 2030 The challenge: QDI: #1 in solving the bioinformatics challenge Bottl
Slide 51: Powerful Analytics to Understand Genomics
Opportunity High-growth bioinformatics market driven by genomics data expansion and advancements in genetic testing and AI Why we win • Highly profitable Software-as-a-Service business with top margins POWERFUL ANALYTICS • Strong #1 position from research to clinical customers TO • Unique competitiv
Slide 52: Capturing Significant Bioinformatics Market Growth
// HIGH-GROWTH MARKET CAPTURING SIGNIFICANT BIOINFORMATICS MARKET GROWTH Strong market opportunity Key growth drivers Bioinformatics market size(1) Genetic testing advancements providing time and cost efficiencies >10% CER CAGR ~$1.0 bn Explosion of genomic data generated by NGS systems Explosion of
Slide 53: Leading from Research to Clinical Customers
// STRONG #1 POSITION #1 LEADING FROM RESEARCH TO CLINICAL CUSTOMERS Addressing large customer base #1 Delivering QDI software solutions for NGS workflow Research – Scientific discovery in Pharma / Biotech Bioinformatics Academia Sample prep Library prep NGS analysis Bioinformatics Government resear
Slide 54: Case Study: Research Advancing Drug Development
// STRONG #1 POSITION CASE STUDY: RESEARCH ADVANCING DRUG DEVELOPMENT Pharma challenge QDI pivotal to drug discovery Over 50,000 scientific publications cite our software Key to understanding disease pathways, targets and measure changes 24 of the Top 25 Pharma companies use QDI Significant number o
Slide 55: Case Study: Clinical Enhancing Patient Outcomes
// STRONG #1 POSITION CASE STUDY: CLINICAL ENHANCING PATIENT OUTCOMES Patient situation QDI-enhanced patient outcome Mutation identification and recommendation by QDI Profile Male (early 70s) Targeted therapy leading to life-saving disease remission Diagnosis QIAGEN Clinical Leukemia linked to rare
Slide 56: Offering Uniquely Profitable Software-as-a-Service Portfolio
// HIGHLY PROFITABLE BUSINESS OFFERING UNIQUELY PROFITABLE SOFTWARE-AS-A-SERVICE PORTFOLIO Data analysis Data interpretation ~$100 mn Research Share of net sales QIAGEN CLC #1 QIAGEN IPA #1 QDI net sales (2023) ~60% OmicSoft #1 COSMIC #1 Human Gene Mutation #1 >80% annual recurring from subscription
Slide 57: Sustained Competitive Edge with Curated Knowledge
// UNIQUE COMPETITIVE EDGE SUSTAINED COMPETITIVE EDGE WITH CURATED KNOWLEDGE Gold standard databases AI with human curation Scientific applications >40 >150 >100,000 scientific and clinical databases Ph.D. scientists ensuring depth, scientific publications leveraging proprietary QIAGEN data breadth
Slide 58: Investing to Extend Market Leadership
// EXTEND MARKET LEADERSHIP INVESTING TO EXTEND MARKET LEADERSHIP ≥$200 mn QDI net sales CER target (2028) Extend leadership in curated Deepen global Invest in new AI and other knowledge commercial reach technologies Expand QIAGEN knowledge base into Adopt SaaS go-to-market NEW Continue advancing so
Slide 59: Expanding AI Leadership with Product Innovations
// EXTEND AI LEADERSHIP EXPANDING AI LEADERSHIP WITH PRODUCT INNOVATIONS 5 AI-enabled offerings today >14 AI-enabled applications by 2028 Pathway analysis Accelerate decision-making NEW 4+ Raw genomic data processing with enhanced AI features upgraded AI-assisted Experimental genomic data matching a
Slide 60: Net Sales 2028 QIAGEN Digital Insights Targets
NET SALES 2028 QIAGEN DIGITAL INSIGHTS TARGETS(1) POWERFUL ANALYTICS TO UNDERSTAND GENOMICS Extend leadership in curated knowledge Expand breadth of knowledge base QDI ≥$200 mn Deepen global commercial reach Adopt SaaS go-to-market approach vs. >$110 mn (2024) Invest in new AI and other technologies
Slide 61: 2028 Targets
2028 TARGETS Roland Sackers Chief Financial Officer COMMITTED TO SOLID PROFITABLE GROWTH June 17, 2024 Capital Markets Day 2024 61
Slide 62: Our 2028 Targets
STRATEGY: COMMITTED TO SOLID PROFITABLE GROWTH OUR 2028 TARGETS Sharpen focus on growth pillars to At least $2 bn sustain profitable growth net sales CER from pillars in 2028 ~7% At least 250 bps Net sales CER CAGR Drive efficiency and digitization to fuel (2024-28) growth investments and profitabil
Slide 63: Delivering Solid Growth Since 2019
// SUSTAIN PROFITABLE GROWTH DELIVERING SOLID GROWTH SINCE 2019 Strong non-COVID growth Improved profitability Healthy cash generation Total net sales Adjusted diluted EPS Operating cash flow +7% +10% +9% CAGR(1) CAGR CAGR ~$2.0 bn $2.07 ~$460 mn ~$1.5 bn ~$330 mn $1.43 2019 2023 2019 2023 2019 2023
Slide 64: Sharpened Pillars Driving 2028 Growth Expansion
// SUSTAIN PROFITABLE GROWTH SHARPENED PILLARS DRIVING 2028 GROWTH EXPANSION QIAGEN Market 2024-28 2028 2024-28 2024-28 Product groups net sales Growth pillars net sales net sales CAGR CER CAGR CER target CER CAGR Sample Low- to mid- QIAcuity dPCR ≥$250 ~$90 mnmn ≥25% >25% >15% technologies single-d
Slide 65: Efficiency and Digital Initiatives Driving Profitability
// DRIVE PERFORMANCE AND PROFITABILITY EFFICIENCY AND DIGITAL INITIATIVES DRIVING PROFITABILITY Adjusted operating income margin CER ≥+250 bps improvement ≥+100 bps ≥ 31% ≥+100 bps ~+50 bps ≥ 28% +50 bps ≥ 28.5% Portfolio streamlining NeuMoDx decision, continued disciplined portfolio management Proc
Slide 66: Operational Excellence: Fostering Efficiency
// DRIVE PERFORMANCE AND PROFITABILITY OPERATIONAL EXCELLENCE: FOSTERING EFFICIENCY Multi-year QIAefficiency program Enabling ≥31% adjusted operating income margin in 2028 while fueling growth through targeted investments Organizational design Portfolio streamlining Process optimization Site network
Slide 67: Digitization: Leveraging AI Technology Across QIAGEN
// DRIVE PERFORMANCE AND PROFITABILITY DIGITIZATION: LEVERAGING AI TECHNOLOGY ACROSS QIAGEN Improve efficiencies through AI and digitization across the value chain Selected areas Spotlight examples Impact Manufacturing Real-time in-process control and enhanced predictive analytics for production pla
Slide 68: Healthy Balance Sheet Enabling Capital Allocation
// ENSURE DISCIPLINED CAPITAL ALLOCATION HEALTHY BALANCE SHEET ENABLING CAPITAL ALLOCATION Debt maturity overview(1) $605 mn $617 mn 105 117 Likely repayment in 2025(2) 500 500 $154 mn $57 mn $77 mn $19 mn 2024 2025 2027 2029 2032 2035 German private placements (Schuldschein) Convertible bonds May c
Slide 69: Proven Disciplined Capital Allocation Approach
// ENSURE DISCIPLINED CAPITAL ALLOCATION PROVEN DISCIPLINED CAPITAL ALLOCATION APPROACH Organic Profitable targeted investments investments into pillars and digitization to fuel profitable business expansion Strong cash flow and healthy Focused Value-creating transactions M&A to enhance portfolio an
Slide 70: 2024-2028 Assumptions
2024-2028 ASSUMPTIONS Net sales: Business excluding NeuMoDx Adjusted tax rate: Moderate changes expected subject to legislation (OECD Pillar Two) Net interest income (expense): Reduced interest income, subject to interest rate environment and refinancing opportunities Shares outstanding: ~210-215 mn
Slide 71: Our 2028 Targets
STRATEGY: COMMITTED TO SOLID PROFITABLE GROWTH OUR 2028 TARGETS Sharpen focus on growth pillars to At least $2 bn sustain profitable growth net sales CER from pillars in 2028 ~7% At least 250 bps Net sales CER CAGR Drive efficiency and digitization to fuel (2024-28) growth investments and profitabil
Slide 72: Building Sustainable Ecosystems for Our Customers
BUILDING SUSTAINABLE ECOSYSTEMS FOR OUR CUSTOMERS Pharma / CROs Academia / hospitals QIAcuity dPCR QIAstat-Dx QIAGEN Digital Insights Clinical labs / test facilities Public agencies Sample technologies QuantiFERON June 17, 2024 Capital Markets Day 2024 72
Slide 73: Q&A Session
COMMITTED TO SOLID Q&A SESSION PROFITABLE GROWTH Capital Markets Day June 17, 2024 June 17, 2024 Capital Markets Day 2024 73
Slide 74: Committed to Solid Profitable Growth
COMMITTED TO SOLID PROFITABLE GROWTH Capital Markets Day June 17, 2024